Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc +1 more source
Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. [PDF]
Narikawa Y +33 more
europepmc +1 more source
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis. [PDF]
Naatz LC +4 more
europepmc +1 more source
Case Report: Bowen's disease treated with PD-1 inhibitor and chemotherapy. [PDF]
Xie X, Chen Q, Zhang J, Peng X.
europepmc +1 more source
Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC. [PDF]
Ya H +8 more
europepmc +1 more source
Correction: Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy. [PDF]
Hirata Y +5 more
europepmc +1 more source
Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype. [PDF]
Desimpel PH +3 more
europepmc +1 more source
Multidimensional Assessment of Neurological Adverse Reactions Related to PD-1 Inhibitors: A Real-World Pharmacovigilance Study. [PDF]
Hu X +12 more
europepmc +1 more source
Frequencies of PD-1 and LAG-3 positive T cells in asthmatic children and their relationship with inflammatory cytokines. [PDF]
Huang J, Zhang G, Yuan W, Tao Y, Yuan H.
europepmc +1 more source

